When Success Rates Go Low, Cell-Based Screens Go High
To Boost Success Rates, Developers are Balancing High-Content and High-Throughput Screening
Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals
Goal Is the Development of Faster, More Affordable Therapies
Top 10 Asia Biopharma Clusters 2018
Chinese Economy, Overseas Investment Scrutiny Challenge the East’s Most Promising Regions
Innovations in Viral Clearance
Mock Viruses, Plant Design, and Rational Testing
For full access to this article login to GEN Select now.
GEN Roundup: Kinase Assays: Too Many Are Never Enough
<i>GEN</i>'s Panel Gives Expert Advice on Which Format Is Best
- No drug developer imagines that every kinase-targeting program can be advanced by any single kinase assay format. Most drug developers recognize that if they are to advance a kinase-targeting program, they will have to sift through multiple kinase assay formats. In all likelihood, the drug developer will identify several ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.